Clinical Trials Directory

Trials / Completed

CompletedNCT00671242

Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake

Correlation of Angiogenesis With 18F-FMT and 18F-FDG Uptake in Non-Small Cell Lung Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
Sponsor
Gunma University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Purpose: L-\[3-18F\]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer (NSCLC). Method: Thirty-seven NSCLC patients were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. Uptake of PET tracers was evaluated with standardized uptake value. VEGF, CD31, CD34, LAT1 and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical staining, and correlated with the clinicopathologic variables and the uptake of PET tracers.

Conditions

Timeline

First posted
2008-05-05
Last updated
2008-05-05

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT00671242. Inclusion in this directory is not an endorsement.

Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake (NCT00671242) · Clinical Trials Directory